1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Cutaneous	_	_	JJ	_	_	_	_	_
2	squamous	_	_	JJ	_	_	_	_	_
3	cell	_	_	NN	_	_	_	_	_
4	carcinoma	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	cSCC	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	second	_	_	JJ	_	_	_	_	_
11	most	_	_	RBS	_	_	_	_	_
12	common	_	_	JJ	_	_	_	_	_
13	type	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	cancer	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	annual	_	_	JJ	_	_	_	_	_
19	incidence	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	over	_	_	IN	_	_	_	_	_
22	one	_	_	CD	_	_	_	_	_
23	million	_	_	CD	_	_	_	_	_
24	globally	_	_	RB	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Chronic	_	_	JJ	_	_	_	_	_
2	ultraviolet	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	UV	_	_	NN	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	exposure	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	suggested	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	responsible	_	_	JJ	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	DNA	_	_	NN	_	_	_	_	_
14	damage	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	normal	_	_	JJ	_	_	_	_	_
17	keratinocytes	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	epidermis	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	which	_	_	WDT	_	_	_	_	_
23	leads	_	_	VBZ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	development	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	skin	_	_	NN	_	_	_	_	_
29	cancers	_	_	NNS	_	_	_	_	_
30	including	_	_	VBG	_	_	_	_	_
31	cSCC	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	detailed	_	_	JJ	_	_	_	_	_
5	underlying	_	_	JJ	_	_	_	_	_
6	molecular	_	_	JJ	_	_	_	_	_
7	mechanisms	_	_	NNS	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	this	_	_	DT	_	_	_	_	_
10	transition	_	_	NN	_	_	_	_	_
11	still	_	_	RB	_	_	_	_	_
12	need	_	_	VBP	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	fully	_	_	RB	_	_	_	_	_
16	elucidated	_	_	VBN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Apoptosis	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	type	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	programmed	_	_	VBN	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	death	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	initiated	_	_	VBN	_	_	_	_	_
13	by	_	_	IN	_	_	_	_	_
14	intrinsic	_	_	JJ	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	extrinsic	_	_	JJ	_	_	_	_	_
17	signals	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	finely-tuned	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	many	_	_	JJ	_	_	_	_	_
22	factors	_	_	NNS	_	_	_	_	_
23	including	_	_	VBG	_	_	_	_	_
24	BCL-2	_	_	NNP	_	_	_	_	_
25	family	_	_	NN	_	_	_	_	_
26	proteins	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	BCL-2	_	_	NNP	_	_	_	_	_
2	family	_	_	NN	_	_	_	_	_
3	members	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	including	_	_	VBG	_	_	_	_	_
6	both	_	_	CC	_	_	_	_	_
7	anti-apoptotic	_	_	JJ	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	pro-apoptotic	_	_	JJ	_	_	_	_	_
10	BCL-2	_	_	NN	_	_	_	_	_
11	family	_	_	NN	_	_	_	_	_
12	proteins	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	govern	_	_	VBP	_	_	_	_	_
15	mitochondrial	_	_	JJ	_	_	_	_	_
16	outer	_	_	JJ	_	_	_	_	_
17	membrane	_	_	NN	_	_	_	_	_
18	permeabilization	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	MOMP	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	regulate	_	_	VB	_	_	_	_	_
24	apoptosis	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	apoptotic	_	_	JJ	_	_	_	_	_
3	cell	_	_	NN	_	_	_	_	_
4	death	_	_	NN	_	_	_	_	_
5	program	_	_	NN	_	_	_	_	_
6	starts	_	_	VBZ	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	MOMP	_	_	NNP	_	_	_	_	_
9	releases	_	_	VBZ	_	_	_	_	_
10	cytochrome	_	_	NN	_	_	_	_	_
11	c	_	_	NN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	cytosol	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	activates	_	_	VBZ	_	_	_	_	_
16	caspase-family	_	_	JJ	_	_	_	_	_
17	proteases	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	initiating	_	_	VBG	_	_	_	_	_
20	apoptotic	_	_	JJ	_	_	_	_	_
21	events	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Tumors	_	_	NNS	_	_	_	_	_
2	develop	_	_	VBP	_	_	_	_	_
3	effective	_	_	JJ	_	_	_	_	_
4	mechanisms	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	resist	_	_	VB	_	_	_	_	_
7	apoptosis	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	thus	_	_	RB	_	_	_	_	_
10	become	_	_	VB	_	_	_	_	_
11	one	_	_	CD	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	hallmark	_	_	JJ	_	_	_	_	_
15	features	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	cancer	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	lead	_	_	JJ	_	_	_	_	_
3	member	_	_	NN	_	_	_	_	_
4	BCL-2	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	its	_	_	PRP$	_	_	_	_	_
7	homologue	_	_	NN	_	_	_	_	_
8	BCL-XL	_	_	NNP	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	BCL2L1	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	featured	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	presence	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	four	_	_	CD	_	_	_	_	_
19	conserved	_	_	VBN	_	_	_	_	_
20	BH	_	_	NNP	_	_	_	_	_
21	domains	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	three	_	_	CD	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	which	_	_	WDT	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	BH1	_	_	NNP	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	BH2	_	_	NNP	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	BH3	_	_	NNP	_	_	_	_	_
33	domains	_	_	NNS	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	are	_	_	VBP	_	_	_	_	_
36	responsible	_	_	JJ	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	their	_	_	PRP$	_	_	_	_	_
39	antiapoptotic	_	_	JJ	_	_	_	_	_
40	role	_	_	NN	_	_	_	_	_
41	mainly	_	_	RB	_	_	_	_	_
42	by	_	_	IN	_	_	_	_	_
43	interactions	_	_	NNS	_	_	_	_	_
44	with	_	_	IN	_	_	_	_	_
45	other	_	_	JJ	_	_	_	_	_
46	proapoptotic	_	_	JJ	_	_	_	_	_
47	members	_	_	NNS	_	_	_	_	_
48	of	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	BCL-2	_	_	NNP	_	_	_	_	_
51	family	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	Inhibiting	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	activities	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	anti-apoptotic	_	_	JJ	_	_	_	_	_
6	BCL-2	_	_	NN	_	_	_	_	_
7	members	_	_	NNS	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	neutralizing	_	_	VBG	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	BH3	_	_	NNP	_	_	_	_	_
14	peptides	_	_	NNS	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	prime	_	_	JJ	_	_	_	_	_
17	cancer	_	_	NN	_	_	_	_	_
18	cells	_	_	NNS	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	death	_	_	NN	_	_	_	_	_
21	has	_	_	VBZ	_	_	_	_	_
22	been	_	_	VBN	_	_	_	_	_
23	regarded	_	_	VBN	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	effective	_	_	JJ	_	_	_	_	_
26	therapeutic	_	_	JJ	_	_	_	_	_
27	modalities	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	another	_	_	DT	_	_	_	_	_
3	way	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	transcriptionally	_	_	RB	_	_	_	_	_
6	or	_	_	CC	_	_	_	_	_
7	post-transcriptionally	_	_	RB	_	_	_	_	_
8	repressing	_	_	VBG	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	expression	_	_	NN	_	_	_	_	_
11	levels	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	anti-apoptotic	_	_	JJ	_	_	_	_	_
14	BCL-2	_	_	NN	_	_	_	_	_
15	members	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	cancer	_	_	NN	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	also	_	_	RB	_	_	_	_	_
20	promising	_	_	JJ	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	mechanism	_	_	NN	_	_	_	_	_
5	regulating	_	_	VBG	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	expression	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	BCL-2	_	_	NNP	_	_	_	_	_
10	family	_	_	NN	_	_	_	_	_
11	members	_	_	NNS	_	_	_	_	_
12	still	_	_	RB	_	_	_	_	_
13	remain	_	_	VBP	_	_	_	_	_
14	unclear	_	_	JJ	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Autophagy	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	evolutionarily-conserved	_	_	JJ	_	_	_	_	_
5	catabolic	_	_	JJ	_	_	_	_	_
6	process	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	during	_	_	IN	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	“	_	_	``	_	_	_	_	_
11	useless	_	_	JJ	_	_	_	_	_
12	”	_	_	''	_	_	_	_	_
13	proteins	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	damaged	_	_	VBN	_	_	_	_	_
16	organelles	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	sequestrated	_	_	VBN	_	_	_	_	_
19	into	_	_	IN	_	_	_	_	_
20	autophagosomes	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	fused	_	_	VBN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	lysosomes	_	_	NNS	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	form	_	_	VB	_	_	_	_	_
27	autolysosomes	_	_	NNS	_	_	_	_	_
28	for	_	_	IN	_	_	_	_	_
29	bulk	_	_	NN	_	_	_	_	_
30	degradation	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	embedded	_	_	VBN	_	_	_	_	_
33	components	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Except	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	dysregulated	_	_	JJ	_	_	_	_	_
4	autophagic	_	_	JJ	_	_	_	_	_
5	process	_	_	NN	_	_	_	_	_
6	defined	_	_	VBN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	type	_	_	NN	_	_	_	_	_
9	II	_	_	NN	_	_	_	_	_
10	programmed	_	_	VBN	_	_	_	_	_
11	cell	_	_	NN	_	_	_	_	_
12	death	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	autophagy	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	generally	_	_	RB	_	_	_	_	_
17	regarded	_	_	VBN	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	protective	_	_	JJ	_	_	_	_	_
20	cellular	_	_	JJ	_	_	_	_	_
21	process	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	recycled	_	_	VBN	_	_	_	_	_
3	peptides	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	nucleotides	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	lipids	_	_	NNS	_	_	_	_	_
8	together	_	_	RB	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	energy	_	_	NN	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	critical	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	maintenance	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	cellular	_	_	JJ	_	_	_	_	_
19	homeostasis	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	support	_	_	NN	_	_	_	_	_
22	tumor	_	_	NN	_	_	_	_	_
23	cells	_	_	NNS	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	survive	_	_	VB	_	_	_	_	_
26	under	_	_	IN	_	_	_	_	_
27	stressful	_	_	JJ	_	_	_	_	_
28	environment	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Autophagy-related	_	_	JJ	_	_	_	_	_
2	genes	_	_	NNS	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	ATGs	_	_	NNS	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	including	_	_	VBG	_	_	_	_	_
8	ULK1	_	_	NNP	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	ATG1	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	ATG3	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	ATG12	_	_	NNP	_	_	_	_	_
17	etc.	_	_	FW	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	involved	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	distinct	_	_	JJ	_	_	_	_	_
24	stages	_	_	NNS	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	autophagy	_	_	NN	_	_	_	_	_
27	:	_	_	:	_	_	_	_	_
28	initiation	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	autophagosome	_	_	NN	_	_	_	_	_
31	nucleation	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	autophagosome	_	_	NN	_	_	_	_	_
34	membrane	_	_	NN	_	_	_	_	_
35	expansion	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	fusion	_	_	NN	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	lysosome	_	_	NN	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	intravesicular	_	_	JJ	_	_	_	_	_
43	components	_	_	NNS	_	_	_	_	_
44	degradation	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Signaling	_	_	VBG	_	_	_	_	_
2	pathways	_	_	NNS	_	_	_	_	_
3	or	_	_	CC	_	_	_	_	_
4	critical	_	_	JJ	_	_	_	_	_
5	factors	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	involved	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	regulating	_	_	VBG	_	_	_	_	_
10	ATG	_	_	NN	_	_	_	_	_
11	genes	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	Class	_	_	NNP	_	_	_	_	_
15	III	_	_	NNP	_	_	_	_	_
16	PI3-kinase	_	_	NNP	_	_	_	_	_
17	complex	_	_	NN	_	_	_	_	_
18	I	_	_	PRP	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	mTORC	_	_	NNP	_	_	_	_	_
21	I	_	_	PRP	_	_	_	_	_
22	complex	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	mTORC	_	_	NNP	_	_	_	_	_
25	II	_	_	NNP	_	_	_	_	_
26	complex	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	Beclin1	_	_	NNP	_	_	_	_	_
29	et	_	_	FW	_	_	_	_	_
30	al.	_	_	FW	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	transcriptional	_	_	JJ	_	_	_	_	_
5	regulation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	ATG	_	_	NNP	_	_	_	_	_
9	genes	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	fully	_	_	RB	_	_	_	_	_
13	explored	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	previous	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Homeobox	_	_	NNP	_	_	_	_	_
7	A9	_	_	NNP	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	HOXA9	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	significantly	_	_	RB	_	_	_	_	_
13	downregulated	_	_	VBN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	identified	_	_	VBN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	tumor	_	_	NN	_	_	_	_	_
18	suppressor	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	cSCC	_	_	NNP	_	_	_	_	_
21	tumors	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	cells	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	HOXA9	_	_	NNP	_	_	_	_	_
2	functions	_	_	VBZ	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	repressing	_	_	VBG	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	proliferation	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	migration	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	invasiveness	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	while	_	_	IN	_	_	_	_	_
13	promoting	_	_	VBG	_	_	_	_	_
14	apoptosis	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	cSCC	_	_	NN	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	mechanisms	_	_	NNS	_	_	_	_	_
5	about	_	_	IN	_	_	_	_	_
6	how	_	_	WRB	_	_	_	_	_
7	HOXA9	_	_	NNP	_	_	_	_	_
8	regulate	_	_	VBP	_	_	_	_	_
9	apoptosis	_	_	NN	_	_	_	_	_
10	has	_	_	VBZ	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	been	_	_	VBN	_	_	_	_	_
13	explored	_	_	VBN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	remain	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	elucidated	_	_	VBN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	found	_	_	VBD	_	_	_	_	_
7	RELA	_	_	NNP	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	p65	_	_	NN	_	_	_	_	_
10	subunit	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	NF-κB	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	transcriptionally	_	_	RB	_	_	_	_	_
16	repressed	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	HOXA9	_	_	NNP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	cSCC	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	RELA	_	_	NNP	_	_	_	_	_
5	transactivates	_	_	VBZ	_	_	_	_	_
6	BCL-XL	_	_	NNP	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	antagonize	_	_	VB	_	_	_	_	_
9	apoptosis	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	ATG	_	_	NN	_	_	_	_	_
12	genes	_	_	NNS	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	ULK1	_	_	NNP	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	ATG3	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	ATG12	_	_	NNP	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	promote	_	_	VB	_	_	_	_	_
23	autophagy	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	highlights	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	HOXA9-NF-κB	_	_	NNP	_	_	_	_	_
6	axis	_	_	NN	_	_	_	_	_
7	regulates	_	_	VBZ	_	_	_	_	_
8	both	_	_	CC	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	apoptosis	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	autophagy	_	_	NN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	promote	_	_	VB	_	_	_	_	_
15	tumor	_	_	NN	_	_	_	_	_
16	development	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	cSCC	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	may	_	_	MD	_	_	_	_	_
22	suggest	_	_	VB	_	_	_	_	_
23	novel	_	_	JJ	_	_	_	_	_
24	intervention	_	_	NN	_	_	_	_	_
25	targets	_	_	NNS	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	cSCC	_	_	NNP	_	_	_	_	_
28	therapy	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

